「isthe first」の検索結果
20件:11~15件目を表示
-

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica
List of Clinical Trial Summaries ※Listed in order of date of first publication Medical Condition Phase Project Code Country Recruitment Status Access to Trial ID Allergic Conjunctivitis 2 SJP-0049 Jap...
https://www.senju.co.jp/english/rd/trial.html -

Ethical Products for Medical Professionals | Business Activities | About Senju | SENJU Pharmaceutical
r the sensory organs that make possible the senses of sight, hearing, smell, taste, and touch. As a first step in pursuing this new avenue of opportunity, Senju Pharmaceutical has entered the promisin...
https://www.senju.co.jp/english/about/business/mp.html -

製品開発方針 | 研究開発活動 | 千寿製薬株式会社
ています。さらに、世界的な視覚障害または失明の主な原因として、白内障・屈折異常(近視・老視など)・加齢黄斑変性・緑内障・糖尿病網膜症などがあることも報告されています。 私たちは眼の疾患に対する高価値(First in Class、Best in Class、患者さまの利便性の向上など)の製品を創出すべく、今後も全力で研究開発活動を進めてまいります。製品戦略上重要と考える対象疾患として「視覚障害また...
https://www.senju.co.jp/rd/policy/ -

stionnaire, the Dry Eye-Related Quality-of-Life Score (DEQS)*3 . This achievement marks the world’s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the ta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -

stionnaire, the Dry Eye-Related Quality-of-Life Score (DEQS)*3 . This achievement marks the world’s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the ta...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf